With the 2021-2022 respiratory syncytial virus (RSV) season approaching, Harvard Pilgrim would like to remind providers of our policy regarding Synagis (palivizumab), an injection of antibodies used to protect high-risk infants from severe RSV disease.
Read more about Synagis for Upcoming RSV Season
Harvard Pilgrim is pleased to announce that our Quality Grant Program, which was established over 21 years ago, will continue to be offered in 2022 and beyond as a combined Point32Health program for providers in both of the heritage Harvard Pilgrim Health Care and Tufts Health Plan networks.
Read more about 2022 Quality Grant: Call for Letters of Intent
As a reminder, we encourage you to visit the COVID-19 page on our provider website to access resources designed to aid you in conducting operations during the pandemic, including any updates on COVID-19-related coverage, policies, and procedures; our COVID-19 coding grid; and our Interim Telemedicine and Telehealth Payment Policy.
Read more about COVID-19 Updates for Providers
Effective for Massachusetts commercial plans issued or renewed on or after Jan. 1, 2022, Harvard Pilgrim will cover the diagnosis and medically necessary treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS).
Read more about 2022 PANDAS and PANS Coverage